QOP
SRPT icon

Quinn Opportunity Partners’s Sarepta Therapeutics SRPT Stock Holding History

Quinn Opportunity Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,843
Closed -$427K – 412
2025
Q4 		$427K Sell
19,843
-356,401
-95% -$7.51M 0.02% 296
2025
Q3 		$7.25M Buy
376,244
+86,522
+30% +$1.54M 0.51% 53
2025
Q2 		$4.95M Buy
+289,722
New +$12.4M 0.41% 67
2024
Q3 		– Sell
-6,516
Closed -$1.03M – 308
2024
Q2 		$1.03M Buy
+6,516
New +$837K 0.12% 130
2016
Q3 		– Sell
-17,500
Closed -$334K – 132
2016
Q2 		$334K Buy
+17,500
New +$324K 0.13% 81

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Quinn Opportunity Partners's SRPT Position: Q1 2026 in Review

Quinn Opportunity Partners sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 19,843 shares — an estimated $427K sold.

Quinn Opportunity Partners first reported a position in SRPT in Q2 2016 and held it in 5 quarters. The position peaked at $7.25M in Q3 2025. 344 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Quinn Opportunity Partners reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Quinn Opportunity Partners sold 19,843 Sarepta Therapeutics shares in Q1 2026, an estimated $427K.
  • Quinn Opportunity Partners first reported a position in Sarepta Therapeutics in Q2 2016 and held it in 5 quarters.
  • Quinn Opportunity Partners's Sarepta Therapeutics position peaked at $7.25M in Q3 2025.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Quinn Opportunity Partners's 13F filing for Q1 2026, filed 15 May 2026.